Scott Power: ASX stocks fall as investors hear mixed news from Cochlear
Cochlear downgrades full-year profit expectations but launches a world first
Monash IVF head Michael Knaap resigns after another embryo mix-up
Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 27 years, gives his take on the ASX healthcare sector for the week and his 'Powerplay' stock pick.
It was a big week of news for the ASX healthcare sector with the bourse's fourth largest biotech Cochlear (ASX:COH) downgrading its FY25 net earnings ~4% to $390-400 million, compared with prior guidance in February of $410-430m, on "slower-than-expected sales growth over the last few months".
Morgans' healthcare analyst Derek Jellinek wrote in a note to clients consensus for the hearing tech company sat at $411m with Morgans at $412m.
While Cochlear continues to expect implant units to grow ~10% in FY25, growth will be weighted to emerging markets as developed market growth has been impacted by slower-than expected market growth and a "small loss" of market share in a few countries.
Cochlear now expects services revenue to decline by low double-digits compared to prior expectations for a single-digit decline.
"COH believes ongoing work to identify and connect with recipients who could benefit from the latest sound processing technology, combined with the introduction of the new off-the-ear Nucleus Kanso 3 sound processor, which is expected to launch in EU and APAC mid-Jun-25, should lift services revenue in FY26," Jellinek wrote.
Following a disappointing H1 FY25 result, Morgans highlighted risks in the services segment (around 25% of sales), driven by slower-than-expected uptake of the Nucleus 8 sound processor, which was launched in FY23, and cost-of-living pressures delaying device replacements.
But in some positive news, Cochlear also announced the launch of Nucleus Nexa, the world's first and only smart cochlear implant system, saying it was the "outcome of a 20 year investment in R&D".
"A couple of key features include upgraded firmwear, the smallest sound processor and internal memory so that has actually countered the profit downgrade they've announced," Power said.
Morgans has a hold rating on Cochlear with a 12-month target price of $285.55.
Monash chief quits following another embryo mixup
A new acting CEO has been appointed to steer the troubled Monash IVF Group (ASX:MVF), which fell ~27% on Tuesday after reporting another embryo implant bungle.
Monash announced on Thursday CEO and managing director Michael Knaap had resigned with CFO and company secretary Malik Jainudeen appointed acting CEO.
In the latest incident a patient's own embryo was mistakenly transferred to them, rather than their partner's embryo as specified in the treatment plan at Monash's Clayton laboratory in Melbourne on June 5.
Monash said it was conducting an internal investigation to determine the cause of the incident and notified the relevant assisted reproductive technology (ART) regulators, the Victorian health regulator and its insurers.
It comes after Monash revealed in April a woman had given birth to a baby that was not hers after receiving the wrong embryo at a Brisbane clinic.
An independent review by Fiona McLeod AO SC regarding that incident is currently ongoing and has been extended, with the findings yet to be disclosed.
Monash confirmed that its updated profit guidance, issued on May 20, remains unchanged, projecting an underlying NPAT of $27.5 million.
Morgans maintains a speculative buy on Monash with a 12-month target price of $1.
Israel strikes on Iran add to market uncertainty
At 1.45pm on Friday the S&P/ASX 200 Health Care index was down 1.1% for the past five days, while the benchmark ASX 200 was flat for the same period.
Markets took a tumble on Friday after reports of Israel strikes against Iran's nuclear sites with the Middle East bracing for retaliation.
Power said the escalating conflict adds further complexity to global equity markets still very much being driven by macroeconomic factors and geopolitical tensions.
"Markets are still very much broader macro driven including with US President Donald Trump's trade and regulatory policies," Power said.
"Investors will now be closely monitoring the escalating tensions in the Middle East."
Power's Powerplay: EBR completes raise, starts US rollout
EBR Systems (ASX:EBR) is Power's stock of the week after announcing completion of a share purchase plan (SPP) and that the first US commercial patients have been implanted with its WiSE CRT System, the world's only wireless solution for pacing the left side of the heart.
The procedures took place at St David's Medical Centre and the Cleveland Clinic, two of several leading US institutions participating in this pilot release of the WiSE CRT System, which was approved by the FDA in April.
EBR said the cases represented two of the main indications for WiSE.
"Clearly, the first commercial patients implanted with WiSE is a key milestone, as EBR has officially transitioned from a pure R&D focus to a commercial entity," Jellinek wrote in a note to clients.
He said importantly, the implants were done in advance of reimbursement and the limited market release of WiSE, which remained on track for October, showcasing the unmet medical need in the initial US$3.6m total addressable market and belief in use of the device.
"As this device is a novel treatment option requiring physician education, we view the LMR, targeting key heart failure centres in the US, as an appropriate strategic way to build familiarity and experience, prior to full market release," he wrote.
"We see sales surpassing US$80m into CY29.
"While certainly not a 'hockey stick', we believe it is a methodical, stage-gated rollout to build strong physician support and closely monitor clinical outcomes, helping to pique interest from any would-be suitor."
The company also announced today it had finished its SPP raising $xxm and adding to a fully underwritten Institutional Placement raising $55.9m completed in May.
Proceeds from the capital raise will be used to advance its US commercialisation strategy for WiSE.
Morgans has a buy rating and 12-month target price of $2.86.
Two positive studies for Avita
Wounds management company Avita Medical (ASX:AVH) has announced the first clinical publication of its Cohealyx product, which is a collagen-based dermal matrix, in the Journal of Surgery.
The publication includes two positive case reports on patients with complex hand wounds treated with Cohealyx.
In both instances, the patients sustained full-thickness burns following syncopal episode (temporary loss of consciousness due to a drop in blood flow to the brain).
The study showed significant acceleration of wound bed vascularisation and autograft readiness, achieving readiness within five to 10 days compared to the typical two to four weeks.
"Clearly, a small sample size and this publication represents the first clinical validation of AVH's preclinical findings but it's a strong start and likely the first of many case-studies to come," Morgans' healthcare analyst Iain Wilkie wrote in a note to clients
Avita also announced a new study of its flagship spray-on skin treatment Recell showed it reduced hospital stays by 36% compared to traditional skin grafts.
Presented at the British Burn Association's annual meeting, the US-based study analysed outcomes for more than 6,300 patients treated with Recell between 2019 and 2024. All patients had burns covering less than 30% of their total body surface area.
The findings showed Recell patients spent on average 6.2 fewer days in hospital, delivering an estimated $300m in healthcare savings over the five-year period.
Wilkie wrote that the share price had continued to remain weak following series of missed guidance expectations and dwindling cash reserves.
"The point with Avita is they've expanded their product range to treat more of the wound complex and what the market is concerned about is do they need to raise additional funds," Power said.
"They've told the market they can see a pathway through to profitability or breakeven by the fourth quarter of this calendar year so as each quarter rolls on we will get more confident that they're able to achieve that."
Morgans has a speculative buy rating on Avita and 12-month target price of $3.76.
Imricor gets CE Mark for NorthStar Mapping System
Imricor Medical Systems (ASX:IMR) has received CE mark (European) certification for its NorthStar Mapping system under the new, more stringent European Union Medical Device Regulations (MDR).
NorthStar has been approved as a Class IIa medical device with the certification received ahead of schedule.
Imricor is advancing technology for real-time interventional cardiac magnetic resonance (iCMR) ablations, enabling cardiac ablation procedures to be guided by live MRI imaging instead of traditional x-ray fluoroscopy.
NorthStar is a key component of its product offering. The certifications follows on from recent European approvals received for its Advantage-MR EP Recorder/Stimulator (Advantage-MR), and its second generation Vision-MR Ablation Catheter.
"Imricor will now phase out first generation products approved under the old EU regulations, replacing them with new MDR approved devices," Power said.
"We expect sales momentum to steadily build over coming quarters."
Power said next catalysts to watch for include additional sales orders in Europe and Middle East and US FDA approval for NorthStar.
Imricor is also undertaking its Vision-MR Ablation of Atrial Flutter (VISABL-AFL) pivotal clinical trial to support FDA approval of its products, which it hopes to achieve in 2025.
In Europe, where Imricor has already received regulatory approval for atrial flutter, the company has started a pivotal VISABL-VT clinical trial for its second indication, ventricular tachycardia (VT).
Morgans has a speculative buy on Monash and 12-month $2.28 target price.
The views, information, or opinions expressed in the interview in this article are solely those of the interviewee and do not represent the views of Stockhead.
Stockhead has not provided, endorsed or otherwise assumed responsibility for any financial product advice contained in this article.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
ABC News
43 minutes ago
- ABC News
Creatine supplements can be effective but experts warn against gummies and dodgy marketing
"If you have a body you can benefit from it." "If you're not taking it, you're missing out." These are just some of the claims about creatine that social media is awash with. As Brisbane based sports dietitian Taryn Richardson says, "creatine is having a real moment". Hype around taking creatine supplements is at an all-time high and there's never been more product options on the market; from cola gummies to "icy blue razz" powders that are mixed with a drink. Creatine is a compound naturally produced by the body and also found in animal-based products like fish and meat. It's found in most muscles in the body, as well as the brain, and used as a source of energy to allow muscles to flex. Our bodies make around half the creatine we need each day (about 2 to 4 grams) but the rest has to come from the food we eat or supplementation. Creatine is one of the most studied supplements and there is extensive evidence it can support muscle growth and improve athletic performance. Emerging research shows it might even help our brains. But some experts are urging consumers to do some research before they buy. "There's this messaging at the moment that everyone should take creatine supplements no matter who they are and what they're doing, and I really disagree with that," Ms Richardson said. Some brands are selling "premium" types of creatine that don't have adequate scientific backing but customers are paying more for them, according to experts. "Just remember these supplement companies have really good marketing teams," said Professor Matthew Cooke, a nutritionist at La Trobe University, who has done extensive research on creatine. There's also "femvertising" of some products with pretty, pink packaging, collagen add-ins and female-centric marketing, with one US brand even calling themselves "Sheatine". Then there's the gummies. Creatine gummies are advertised as a delicious and easy-to-take option but independent testing has repeatedly shown some contain almost zero creatine. One popular brand sold in Australia called PUSH was forced to halt all sales after testing showed their gummies were significantly underdosed with creatine. Sydney-based personal trainer James Smith was skeptical about the gummy products and whether they met their label claims so he sent nine brands for testing at independent lab Eurofins. All of the testing was made public and only one brand, Wellboost's strawberry banana gummies, contained the advertised 5 grams of creatine. PUSH's strawberry flavour gummies returned a creatine reading of 0.102 grams per serving when it should have been 5 grams. Their apple flavour came in at 0.112 grams. PUSH was charging $59.95 for a 30-day supply. Anaesthetic technician Tina Hill had been taking PUSH gummies for four months before learning they were just "expensive lollies". "I was just throwing money down the drain," she said. Ms Hill said she heard about creatine online and wanted to support her strength training but was also interested in any potential cognitive benefits it could give her. "I saw all of those well-known fitness influencers who had come from a competitive background were promoting PUSH gummies on social media and it seemed reliable," she said. In a statement, PUSH told the ABC it accepted full responsibility for the underdosing and was now suing its former manufacturer. PUSH has accused the manufacturer, which is based in China, of altering the product formula without their knowledge. "Production is now underway with a new Australian based manufacturer to strengthen quality control and prevent issues like this from happening again," PUSH said. "Moving forward every batch of PUSH gummies will be independently tested by Eurofins US." But experts say consumers should avoid all creatine gummies brands for now. "I think these companies have good intentions but it comes down to the production — with the process of making gummies such as heating likely decreasing the levels of creatine," Professor Cooke said. Ms Richardson agreed. "For now I'm telling my clients to stick with powders — they are a lot cheaper anyway," she said. Ms Hill switched to a powder supplement and said she is finally feeling the effects of creatine. "A few weeks in I do feel like I've seen a huge improvement in my fitness levels and just my general wellbeing." Women generally have lower levels of creatine as they tend to get a lower intake through their diet and have lower muscle mass than men, which means they have lower creatine storage. Studies have also shown vegetarians and vegans have lower baseline levels. "A lot of us probably aren't getting enough creatine from our diet as we're heading towards more plant-based diets or at least reducing the amount of meat we eat," Professor Cooke said. Evidence shows creatine supplementation can boost the total creatine in your muscles by around 20 to 40 per cent. Some people do this quickly by starting with a "loading" phase of 20 grams per day for a week and then lowering to 5 grams per day. Loading isn't necessary though, Professor Cooke said, because you get the same results by starting at 5 grams per day, it will just take a bit longer. For most people it will result in more power and strength for explosive bursts of exercise and it improves recovery after exercise-related muscle damage as well as sarcopenia (loss of muscle as we age) if taken in conjunction with resistance training. Recently, researchers started delving deeper into the potential benefits of creatine among women and how it might assist during hormonal fluctuations. During menopause, estrogen and progesterone levels decline significantly which may negatively impact creatine metabolism so supplementation could be beneficial at this time, Professor Cooke said. Research has shown creatine supplementation can help post-menopausal women with physical function when combined with resistance training and now experts want to explore how it might support bone health during perimenopause when bone density starts to decrease. It's early days but research is also suggesting supplementation may benefit pre-menopausal women during their menstrual cycles when there's varying levels of creatine metabolism and fatigue. Some brands are now shamelessly trying to capture the female market by using taglines like "craft your perfect peach" or advertising "creatine for women" when it's exactly the same as the "genderless" creatine on the market. Professor Cooke said some brands may be capitalising on the recent research that's been more focused on women. "I know some marketing will take advantage of this but in the research space it's really great to see this research in the female population." Creatine is mostly stored in muscles but a small amount is also found in the brain and there's evidence it may benefit mood and cognitive function, particularly for those who are sleep deprived. It could even help with recovery from traumatic brain injuries. More high-quality research is needed but some studies show it could potentially help people with Alzheimer's disease. Jose Antonio is a professor of health and human performance at Nova Southeastern University in Florida and said he was particularly excited by the neuroscience research into creatine. "Even if you don't care about the muscular strength side of things I tell my students they should take it for their brain because in the last five years there's been more data showing it can help with cognitive processes," Professor Antonio said. It's worth nothing though that approximately 20 to 30 per cent of people are non-responders to creatine supplementation, meaning that they see little to no benefit from it. Creatine can be bought in a few different forms and the vast majority of research is on creatine monohydrate (creatine molecule + water molecule). But some brands are selling new formulations in which they bond the creatine molecule to other compounds to make: Many brands selling these claim they are up to five times more effective or better absorbed than creatine monohydrate. "That's baloney," Professor Jose Antonio said, "not only are they more expensive, they don't work better. "Some of them claim, 'this is better absorbed than creatine monohydrate' but monohydrate is 99.9 per cent absorbed so you're not going to get any better absorption." Professor Cooke said some of these may actually be less effective and he wouldn't recommend buying anything other than creatine monohydrate. Creatine supplements are safe and have limited side effects — some people may experience some bloating but that can generally be minimised by taking a lower dose or taking it with meals. But Ms Richardson doesn't recommend heading straight to the supplement aisle saying a "food first" approach is best. "There's no point adding sprinkles to the cake if you don't have your cake baked first — you need to build a foundation of good day-to-day nutrition through your diet and only then would I look to add supplements to that." Professor Cooke said taking a creatine supplement was personal preference but he is glad it's no longer seen as something just for "gym heads". "I think the key thing here is it's safe and there's benefits across the life span."
The Australian
2 hours ago
- The Australian
Varroa mites found in beehives in Gippsland, Victoria
A deadly parasite that infests beehives and kills honey bees has spread through regional Victoria. Varroa mites have been detected in beehives throughout the Gippsland region, putting apiarists on alert to monitor their hives for any infestation. Gippsland Apiarist Association president Stan Glowacki said once a mite got into a beehive it could build up numbers where it killed off the hive within about six to nine months. 'If you have 400 hives that could be quite a financial hit to your operation,' he said. 'It's going to affect every beekeeper, it does not matter whether they have one hive or 1000 hives.' Varroa destructors are a parasite of adult honey bees and broods that weaken and kill honey bee colonies and transmit viruses, according to Victoria Agriculture. They are a major problem for commercial and hobby beekeepers once they become established. Varroa mites were first detected in NSW in June 2022. A national eradication response saw 14,000 hives euthanised before it was determined it was not feasible to achieve total elimination. Authorities and beekeepers now manage the pest, which can cost about $40 a year per hive, according to Mr Glowacki. 'It's a little parasitic mite that moves on the bees,' Mr Glowacki said. 'To scale it up to human size, it's the equivalent of having a parasite the size of a dinner plate stuck on your body, sucking out your blood.' He said once a female mite got inside a hive and a brood hatched it was an exponential threat. 'It's very worrying even for a small backyard beekeeper. Nobody wants to lose their bees,' he said. 'If you don't monitor your hives and manage the mite you're going to lose your hives. 'Eventually we're going to get to the stage where the industry is going to know the genetics and have hives that can manage the mite without the use of chemicals. 'But until we get to that stage people will lose hives and pay for the chemicals to try and keep their hives alive.' Victoria Agriculture has been contacted for comment. NewsWire Despite Australia's birth rate struggling to recover to pre-Covid levels and it's clear impact on an issue the government is desperate to fix – one thing is off the table. NewsWire Despite Australia's birth rate struggling to recover to pre-Covid levels and it's clear impact on an issue the government is desperate to fix – one thing is off the table.
The Australian
2 hours ago
- The Australian
South Australia bans soy sauce fish packets in plastics fight
Takeaway soy sauce fish packets will soon be a thing of the past in South Australia. Straws attached to drink containers and spoons and forks attached to pre-packaged foods are also on the chopping block from September 1, along with plastic fruit stickers. 'These bans encourage reusable, recyclable or compostable alternatives,' South Australian Deputy Premier Susan Close said. 'South Australians are increasingly looking at ways to reduce their reliance on single-use plastics which devastate our environment. Plastic soy sauce fish packets will be banned in South Australia in September. Picture: Supplied 'The state government will continue to assist South Australian businesses via various programs to assist them transition. 'Many South Australian businesses have already moved away from single-use items and are embracing reusable and compostable items.' In September 2023, the government banned plastic stemmed cotton buds, plastic pizza savers, single-use plastic plates and bowls. Then a year later, it banned plastic bags, plastic balloon sticks, plastic balloon ties, plastic confetti, plastic bread tags and single-use plastic coffee cups and plastic lids, among other items. SA Deputy Premier Susan Close said the ban on single use plastics would help preserve the environment. Picture: NewsWire / Naomi Jellicoe Since 2021, the government credits local business with removing more than eight million single-use plastic items. Evergreen Deli's Elliott Horner said the move away from plastics would help preserve the natural world. 'Being nestled within Adelaide Botanic Garden, environmental consciousness is our constant companion, as we care for the very place we call home,' the venue and events manager said. Multiple states have moved to ban single use plastics, including NSW and Victoria. Read related topics: Adelaide Duncan Evans Reporter Duncan Evans is a reporter for News Corp's NewsWire service, based in Adelaide. Before NewsWire, he worked as a resources and politics reporter for The Daily Mercury in Mackay, Queensland and as a reporter at CQ Today, an independent newspaper based in Rockhampton. He was raised in Emerald and Brisbane and studied English Literature and American Studies at the University of Sydney. He began his career in journalism working for the Jakarta Post in Indonesia for over two years as an editor, translator and writer. He is fluent in Indonesian. @Duncanevans01 Duncan Evans
